{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:58:05Z","timestamp":1787025485999,"version":"build-2736575974"},"reference-count":174,"publisher":"IMR Press","issue":"6","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>The treatment options for multiple myeloma (MM) have undergone significant transformation with the advent of immunotherapy. Novel therapies that focus on tumor antigens now drive advances in MM research. Bispecific antibodies (bsAbs) leverage revolutionary advances in bioengineering techniques and embody the second generation of antibody-based tumor therapy. Recent studies on bsAbs in relapsed\/refractory MM cases have revealed remarkable efficacy and acceptable safety profiles. The approval of elranatamab and teclistamab represents the next step in the development of bsAbs for the treatment of MM. This review article addresses the antigen targeting, efficacy, safety, and strategies in the application of bsAbs against treatment-resistant MM, with a focus on clinical trials and real-world data.<\/jats:p>","DOI":"10.31083\/j.fbl2906216","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T06:43:32Z","timestamp":1718693012000},"source":"Crossref","is-referenced-by-count":6,"title":["Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy"],"prefix":"10.31083","volume":"29","author":[{"given":"Moran","family":"Wang","sequence":"first","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofan","family":"Wang","sequence":"first","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Deng","sequence":"first","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafang","family":"Wang","sequence":"first","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Sun","sequence":"first","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Luo","sequence":"first","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"first","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: a Cancer Journal for Clinicians. 2023; 73: 17\u201348.","DOI":"10.3322\/caac.21763"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Palumbo A, Anderson K. Multiple myeloma. The New England Journal of Medicine. 2011; 364: 1046\u20131060.","DOI":"10.1056\/NEJMra1011442"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Moreau P, de Wit E. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. British Journal of Haematology. 2017; 179: 198\u2013218.","DOI":"10.1111\/bjh.14780"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Varga C, Laubach JP, Anderson KC, Richardson PG. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. British Journal of Haematology. 2018; 181: 433\u2013446.","DOI":"10.1111\/bjh.15116"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, et al. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia. 2018; 32: 986\u2013995.","DOI":"10.1038\/leu.2017.331"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Swan D, Lynch K, Gurney M, O\u2019Dwyer M. Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma. Therapeutic Advances in Hematology. 2019; 10: 2040620719854171.","DOI":"10.1177\/2040620719854171"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Madduri D, Dhodapkar MV, Lonial S, Jagannath S, Cho HJ. SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents. Clinical Lymphoma, Myeloma & Leukemia. 2019; 19: 537\u2013544.","DOI":"10.1016\/j.clml.2019.08.002"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Lin Q, Zhao J, Song Y, Liu D. Recent updates on CAR T clinical trials for multiple myeloma. Molecular Cancer. 2019; 18: 154.","DOI":"10.1186\/s12943-019-1092-1"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. Journal of Hematology & Oncology. 2015; 8: 130.","DOI":"10.1186\/s13045-015-0227-0"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Kontermann RE. Dual targeting strategies with bispecific antibodies. MAbs. 2012; 4: 182\u2013197.","DOI":"10.4161\/mabs.4.2.19000"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Krishnamurthy A, Jimeno A. Bispecific antibodies for cancer therapy: A review. Pharmacology & Therapeutics. 2018; 185: 122\u2013134.","DOI":"10.1016\/j.pharmthera.2017.12.002"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nature Reviews. Drug Discovery. 2014; 13: 655\u2013672.","DOI":"10.1038\/nrd4363"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discovery Today. 2015; 20: 838\u2013847.","DOI":"10.1016\/j.drudis.2015.02.008"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017; 9: 182\u2013212.","DOI":"10.1080\/19420862.2016.1268307"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Mueller T, Freystein J, Lucas H, Schmoll HJ. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model. Molecules (Basel, Switzerland). 2019; 24: 2865.","DOI":"10.3390\/molecules24162865"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Wu SC, Chen YJ, Wang HC, Chou MY, Chang TY, Yuan SS, et al. Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2\/neu- and EGFR-Expressing Tumors. Theranostics. 2016; 6: 118\u2013130.","DOI":"10.7150\/thno.13069"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nature Medicine. 2012; 18: 1570\u20131574.","DOI":"10.1038\/nm.2942"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"de Gast GC, van de Winkel JG, Bast BE. Clinical perspectives of bispecific antibodies in cancer. Cancer Immunology, Immunotherapy: CII. 1997; 45: 121\u2013123.","DOI":"10.1007\/s002620050412"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"van Spriel AB, van Ojik HH, van De Winkel JG. Immunotherapeutic perspective for bispecific antibodies. Immunology Today. 2000; 21: 391\u2013397.","DOI":"10.1016\/S0167-5699(00)01659-5"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Chan WK, Kang S, Youssef Y, Glankler EN, Barrett ER, Carter AM, et al. A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma. Cancer Immunology Research. 2018; 6: 776\u2013787.","DOI":"10.1158\/2326-6066.CIR-17-0649"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S, et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood. 2006; 107: 1955\u20131962.","DOI":"10.1182\/blood-2005-05-2177"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood. 2018; 131: 30\u201338.","DOI":"10.1182\/blood-2017-06-741058"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Wu Z, Cheung NV. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics. Pharmacology & Therapeutics. 2018; 182: 161\u2013175.","DOI":"10.1016\/j.pharmthera.2017.08.005"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Zhou X, Einsele H, Danhof S. Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma. Journal of Clinical Medicine. 2020; 9: 2166.","DOI":"10.3390\/jcm9072166"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020; 34: 985\u20131005.","DOI":"10.1038\/s41375-020-0734-z"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, et al. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5\/CD3 and Is a Requirement for Myeloma Cell Killing. Cancer Cell. 2017; 31: 383\u2013395.","DOI":"10.1016\/j.ccell.2017.02.001"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Wei J, Yang Y, Wang G, Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Frontiers in Immunology. 2022; 13: 1035276.","DOI":"10.3389\/fimmu.2022.1035276"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Tamura H, Ishibashi M, Sunakawa M, Inokuchi K. Immunotherapy for Multiple Myeloma. Cancers. 2019; 11: 2009.","DOI":"10.3390\/cancers11122009"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000; 404: 995\u2013999.","DOI":"10.1038\/35010115"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Current Biology: CB. 2000; 10: 785\u2013788.","DOI":"10.1016\/S0960-9822(00)00566-2"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Thompson JS, Schneider P, Kalled SL, Wang L, Lefevre EA, Cachero TG, et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. The Journal of Experimental Medicine. 2000; 192: 129\u2013135.","DOI":"10.1084\/jem.192.1.129"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Hatzoglou A, Roussel J, Bourgeade MF, Rogier E, Madry C, Inoue J, et al. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. Journal of Immunology (Baltimore, Md.: 1950). 2000; 165: 1322\u20131330.","DOI":"10.4049\/jimmunol.165.3.1322"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. British Journal of Haematology. 2012; 158: 727\u2013738.","DOI":"10.1111\/j.1365-2141.2012.09241.x"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Panowski SH, Kuo T, Chen A, Geng T, Van Blarcom TJ, Lindquist K, et al. Preclinical Evaluation of a Potent Anti-Bcma CD3 Bispecific Molecule for the Treatment of Multiple Myeloma. Blood. 2016; 128: 383.","DOI":"10.1182\/blood.V128.22.383.383"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nature Medicine. 2023; 29: 2570\u20132576.","DOI":"10.1038\/s41591-023-02589-w"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nature Medicine. 2023; 29: 2259\u20132267.","DOI":"10.1038\/s41591-023-02528-9"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Tomasson M, Iida S, Niesvizky R, Mohty M, Bahlis NJ, Martinez-Lopez J, et al. Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 2023; 142: 3385.","DOI":"10.1182\/blood-2023-182130"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Kyle RP, Sinyavskaya L, et al. Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future Oncology (London, England). 2024. (online ahead of print)","DOI":"10.2217\/fon-2023-0995"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, et al. A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician\u2019s choice of treatment in patients with triple-class exposed\/refractory multiple myeloma. Current Medical Research and Opinion. 2024; 40: 199\u2013207.","DOI":"10.1080\/03007995.2023.2277850"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Advances. 2020; 4: 4538\u20134549.","DOI":"10.1182\/bloodadvances.2020002393"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Karlin L, Benboubker L, Nahi H, San-Miguel J, Trancucci D, et al. Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study. Journal of Clinical Oncology. 2023; 41: 8034.","DOI":"10.1200\/JCO.2023.41.16_suppl.8034"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. The New England Journal of Medicine. 2022; 387: 495\u2013505.","DOI":"10.1056\/NEJMoa2203478"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Asoori S, Popat R, Mart\u00ednez-Lopez J, Kastritis E, Brunaldi L, Bansal R, et al. Real-World Evaluation of Teclistamab for the Treatment of Relapsed\/Refractory Multiple Myeloma (RRMM). Blood. 2023; 142: 3347.","DOI":"10.1182\/blood-2023-190793"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Gordon B, Fogel L, Varma G, Mejia Saldarriaga M, Ahn J, Aleman A, et al. Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial. Blood. 2023; 142: 4741.","DOI":"10.1182\/blood-2023-181304"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A, et al. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia. 2024; 38: 365\u2013371.","DOI":"10.1038\/s41375-024-02154-5"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer Journal. 2024; 14: 35.","DOI":"10.1038\/s41408-024-01003-z"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Dima D, Sannareddy A, Ahmed N, Davis JA, Shaikh H, Mahmoudjafari Z, et al. Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study. Blood. 2023; 142: 3330.","DOI":"10.1182\/blood-2023-180458"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Lachenal F, Lebreton P, Bouillie S, Pica GM, Aftisse H, Pascal L, et al. Teclistamab in Relapsed Refractory Multiple Myeloma Patients on Dialysis: A French Experience. Blood. 2023; 142: 4739.","DOI":"10.1182\/blood-2023-180660"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, et al. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. Cancer Cell. 2017; 31: 396\u2013410.","DOI":"10.1016\/j.ccell.2017.02.002"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Klein C, Schaefer W, Regula JT, Dumontet C, Brinkmann U, Bacac M, et al. Engineering therapeutic bispecific antibodies using CrossMab technology. Methods (San Diego, Calif.). 2019; 154: 21\u201331.","DOI":"10.1016\/j.ymeth.2018.11.008"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Costa LJ, Wong SW, Berm\u00fadez A, de la Rubia J, Mateos M-V, Ocio EM, et al. First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial. Blood. 2019; 134: 143.","DOI":"10.1182\/blood-2019-122895"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Wong SW, Bar N, Paris L, Hofmeister CC, Hansson M, Santoro A, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study. Blood. 2022; 140: 400\u2013402.","DOI":"10.1182\/blood-2022-159009"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Bar N, Mateos MV, Ribas P, Hansson M, Paris L, Hofmeister CC, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) \u00d7 CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study. Blood. 2023; 142: 2011.","DOI":"10.1182\/blood-2023-180013"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Voorhees PM, D\u2019Souza A, Weisel K, Hurd DD, Teipel R, Chung A, et al. A Phase 1 First-in-Human Study of Abbv-383, a BCMA \u00d7 CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed\/Refractory Multiple Myeloma. Blood. 2022; 140: 4401\u20134404.","DOI":"10.1182\/blood-2022-167008"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Vij R, Kumar SK, D\u2019Souza A, McKay JT, Voorhees PM, Chung A, et al. Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed\/Refractory Multiple Myeloma. Blood. 2023; 142: 3378.","DOI":"10.1182\/blood-2023-182388"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"DiLillo DJ, Olson K, Mohrs K, Meagher TC, Bray K, Sineshchekova O, et al. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Advances. 2021; 5: 1291\u20131304.","DOI":"10.1182\/bloodadvances.2020002736"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Lee HC, Bumma N, Richter JR, Dhodapkar MV, Hoffman JE, Suvannasankha A, et al. LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma. Journal of Clinical Oncology. 2023; 41: 8006.","DOI":"10.1200\/JCO.2023.41.16_suppl.8006"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Jagannath S, Richter J, Dhodapkar MV, Hoffman JE, Lee HC, Suvannasankha A, et al. Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed\/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study. Blood. 2023; 142: 4746.","DOI":"10.1182\/blood-2023-177968"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Plesner T, Harrison SJ, Quach H, Lee CH, Bryant A, Vangsted AJ, et al. A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM). Blood. 2021; 138: 2755.","DOI":"10.1182\/blood-2021-147418"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet (London, England). 2021; 398: 665\u2013674.","DOI":"10.1016\/S0140-6736(21)01338-6"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Goodridge JP, \u00d6nfelt B, Malmberg KJ. Newtonian cell interactions shape natural killer cell education. Immunological Reviews. 2015; 267: 197\u2013213.","DOI":"10.1111\/imr.12325"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Plesner T, Harrison SJ, Quach H, Lee C, Bryant A, Vangsted A, et al. Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA\/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma. Clinical Hematology International. 2023; 5: 43\u201351.","DOI":"10.1007\/s44228-022-00023-5"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Schjesvold F, Spencer A, Cohen YC, Ocio EM, L\u00f3pez-Pardo J, Cafro AM, et al. Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA\u00d7CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and\/or Refractory Multiple Myeloma. Blood. 2023; 142: 4752.","DOI":"10.1182\/blood-2023-177908"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Raab MS, Cohen YC, Schjesvold F, Aardalen K, Oka A, Spencer A, et al. Preclinical discovery and initial clinical data of WVT078, a BCMA \u00d7 CD3 bispecific antibody. Leukemia. 2023; 37: 1349\u20131360.","DOI":"10.1038\/s41375-023-01883-3"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Sun M, Qi J, Qiu L, Jin J, Li X, Wei Y, et al. A Phase 1 First-in-Human Monotherapy Study of F182112, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 2023; 142: 1978.","DOI":"10.1182\/blood-2023-178948"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Atamaniuk J, Gleiss A, Porpaczy E, Kainz B, Grunt TW, Raderer M, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. European Journal of Clinical Investigation. 2012; 42: 953\u2013960.","DOI":"10.1111\/j.1365-2362.2012.02679.x"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Frigyesi I, Adolfsson J, Ali M, Christophersen MK, Johnsson E, Turesson I, et al. Robust isolation of malignant plasma cells in multiple myeloma. Blood. 2014; 123: 1336\u20131340.","DOI":"10.1182\/blood-2013-09-529800"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Laurent SA, Hoffmann FS, Kuhn PH, Cheng Q, Chu Y, Schmidt-Supprian M, et al. \u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells. Nature Communications. 2015; 6: 7333.","DOI":"10.1038\/ncomms8333"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Kodama T, Kochi Y, Nakai W, Mizuno H, Baba T, Habu K, et al. Anti-GPRC5D\/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma. Molecular Cancer Therapeutics. 2019; 18: 1555\u20131564.","DOI":"10.1158\/1535-7163.MCT-18-1216"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Science Translational Medicine. 2019; 11: eaau7746.","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Pillarisetti K, Edavettal S, Mendon\u00e7a M, Li Y, Tornetta M, Babich A, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020; 135: 1232\u20131243.","DOI":"10.1182\/blood.2019003342"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Schinke CD, Touzeau C, Minnema MC, van de Donk NWCJ, Rodr\u00edguez-Otero P, Mateos MV, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). Journal of Clinical Oncology. 2023; 41: 8036.","DOI":"10.1200\/JCO.2023.41.16_suppl.8036"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Sanchez L, Schinke C, Krishnan A, Berdeja JG, van de Donk NWCJ, Mateos MV, et al. Clinical Outcomes of Subsequent Therapies in Patients with Relapsed\/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1\/2 MonumenTAL-1 Study. Blood. 2023; 142: 2007.","DOI":"10.1182\/blood-2023-182330"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Jakubowiak AJ, Anguille S, Karlin L, Chari A, Schinke C, Rasche L, et al. Updated Results of Talquetamab, a GPRC5D\u00d7CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1\/2 MonumenTAL-1 Study. Blood. 2023; 142: 3377.","DOI":"10.1182\/blood-2023-187242"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Matous J, Biran N, Perrot A, Berdeja JG, Dorritie K, Elssen JV, et al. Talquetamab + Pomalidomide in Patients with Relapsed\/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study. Blood. 2023; 142: 1014.","DOI":"10.1182\/blood-2023-187706"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Dholaria BR, Weisel K, Mateos MV, Goldschmidt H, Martin TG, Morillo D, et al. Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Updated TRIMM-2 results. Journal of Clinical Oncology. 2023; 41: 8003.","DOI":"10.1200\/JCO.2023.41.16_suppl.8003"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Harrison SJ, Riley CH, Manier S. Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): analysis of patient- and disease-related factors associated with responses. Abstract OA-05. In International Myeloma Society 20th Annual Meeting and Exposition: Athens, Greece. 2023.","DOI":"10.1016\/S2152-2650(23)01572-0"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Wang B, Huang X, Sun J, Qin Y, Shang H, Li T, et al. Lbl-034, a Highly Differentiated T-Cell Engaging Bispecific Antibody Targeting GPRC5D for the Treatment of Relapsed or Refractory Multiple Myeloma. Blood. 2023; 142: 4672.","DOI":"10.1182\/blood-2023-181395"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Liu Y, Zhou YQ, Nie L, Zhu SS, Li N, Wu ZH, et al. BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with GPRC5D Binding, Has Potent Antitumor Activities in Multiple Myeloma. Cancers. 2023; 15: 5774.","DOI":"10.3390\/cancers15245774"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Capone M, Bryant JM, Sutkowski N, Haque A. Fc Receptor-Like Proteins in Pathophysiology of B-cell Disorder. Journal of Clinical & Cellular Immunology. 2016; 7: 427.","DOI":"10.4172\/2155-9899.1000427"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, et al. Elevation of soluble CD307 (IRTA2\/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia. 2007; 21: 169\u2013174.","DOI":"10.1038\/sj.leu.2404445"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Polson AG, Zheng B, Elkins K, Chang W, Du C, Dowd P, et al. Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. International Immunology. 2006; 18: 1363\u20131373.","DOI":"10.1093\/intimm\/dxl069"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Polson AG, Zheng B, Elkins K, Lau J, Go MAT, Scales SJ, et al. FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma. Blood. 2009; 114: 3836.","DOI":"10.1182\/blood.V114.22.3836.3836"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012; 26: 349\u2013355.","DOI":"10.1038\/leu.2011.204"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Hatzivassiliou G, Miller I, Takizawa J, Palanisamy N, Rao PH, Iida S, et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity. 2001; 14: 277\u2013289.","DOI":"10.1016\/S1074-7613(01)00109-1"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, et al. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunology, Immunotherapy: CII. 2010; 59: 1197\u20131209.","DOI":"10.1007\/s00262-010-0844-y"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Lesokhin AM, Richter J, Trudel S, Cohen AD, Spencer A, Forsberg PA, et al. Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed\/Refractory Multiple Myeloma: Early Experience from a Phase I Study. Blood. 2022; 140: 4415\u20134417.","DOI":"10.1182\/blood-2022-157547"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Cohen AD, Hwang WT, Susanibar-Adaniya S, Vogl DT, Garfall AL, Waxman A, et al. Sequential T-Cell Engagement for Myeloma (\u201cSTEM\u201d) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy. Blood. 2023; 142: 3389.","DOI":"10.1182\/blood-2023-187409"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. American Journal of Clinical Pathology. 2004; 121: 482\u2013488.","DOI":"10.1309\/74R4-TB90-BUWH-27JX"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leukemia Research. 2001; 25: 1\u201312.","DOI":"10.1016\/S0145-2126(00)00093-X"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Bonello F, D\u2019Agostino M, Moscvin M, Cerrato C, Boccadoro M, Gay F. CD38 as an immunotherapeutic target in multiple myeloma. Expert Opinion on Biological Therapy. 2018; 18: 1209\u20131221.","DOI":"10.1080\/14712598.2018.1544240"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Chen X, Wong OK, Reiman L, Sherbenou DW, Post L. CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma. Molecular Cancer Therapeutics. 2024; 23: 127\u2013138.","DOI":"10.1158\/1535-7163.MCT-23-0052"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Richter JR, Landgren CO, Kauh JS, Back J, Salhi Y, Reddy V, et al. Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed\/refractory multiple myeloma. Journal of Clinical Oncology. 2018; 36: TPS3132.","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3132"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Doucey MA, Pouleau B, Estoppey C, Stutz C, Croset A, Laurendon A, et al. ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma. Journal of Clinical Oncology. 2021; 39: 8044.","DOI":"10.1200\/JCO.2021.39.15_suppl.8044"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Kapoor P, Stevens DA, Leleu X, Belhadj Merzoug K, Karlin L, Manier S, et al. Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM). Blood. 2023; 142: 3339.","DOI":"10.1182\/blood-2023-186664"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Kazandjian D, Quach H, Sia H, Ho PJ, Spencer A, Schroeder MA, et al. Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM). Blood. 2023; 142: 4707.","DOI":"10.1182\/blood-2023-186241"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Critical Reviews in Oncology\/hematology. 2013; 88: 168\u2013177.","DOI":"10.1016\/j.critrevonc.2013.04.003"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2008; 14: 2775\u20132784.","DOI":"10.1158\/1078-0432.CCR-07-4246"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Chung C. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy. Pharmacotherapy. 2017; 37: 129\u2013143.","DOI":"10.1002\/phar.1871"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008; 112: 1329\u20131337.","DOI":"10.1182\/blood-2007-08-107292"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Lum LG, Thakur A, Elhakiem A, Alameer L, Dinning E, Huang M. Anti-CS1 \u00d7 Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1+ Myeloma Cells and Release Type-1 Cytokines. Frontiers in Oncology. 2020; 10: 544.","DOI":"10.3389\/fonc.2020.00544"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Beauvais DM, Rapraeger AC. Syndecans in tumor cell adhesion and signaling. Reproductive Biology and Endocrinology: RB&E. 2004; 2: 3.","DOI":"10.1186\/1477-7827-2-3"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi JF, et al. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. British Journal of Haematology. 1998; 100: 637\u2013646.","DOI":"10.1046\/j.1365-2141.1998.00623.x"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Beauvais DM, Jung O, Yang Y, Sanderson RD, Rapraeger AC. Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth. Cancer Research. 2016; 76: 4981\u20134993.","DOI":"10.1158\/0008-5472.CAN-16-0232"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Zou J, Chen D, Zong Y, Ye S, Tang J, Meng H, et al. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma. Cancer Science. 2015; 106: 512\u2013521.","DOI":"10.1111\/cas.12631"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Jagannath S, Chanan-Khan A, Heffner LT, Avigan D, Zimmerman TM, Lonial S, et al. BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed\/Refractory Multiple Myeloma. Blood. 2011; 118: 305.","DOI":"10.1182\/blood.V118.21.305.305"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Experimental Hematology & Oncology. 2012; 1: 36.","DOI":"10.1186\/2162-3619-1-36"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nature Reviews. Rheumatology. 2009; 5: 572\u2013577.","DOI":"10.1038\/nrrheum.2009.184"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"Robillard N, Wuill\u00e8me S, Moreau P, B\u00e9n\u00e9 MC. Immunophenotype of normal and myelomatous plasma-cell subsets. Frontiers in Immunology. 2014; 5: 137.","DOI":"10.3389\/fimmu.2014.00137"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"Hajek R, Okubote SA, Svachova H. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. British Journal of Haematology. 2013; 163: 551\u2013564.","DOI":"10.1111\/bjh.12563"},{"key":"ref111","doi-asserted-by":"crossref","unstructured":"Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, et al. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. The New England Journal of Medicine. 2015; 373: 1040\u20131047.","DOI":"10.1056\/NEJMoa1504542"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 2019; 4: e127684.","DOI":"10.1172\/jci.insight.127684"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. The Lancet. Haematology. 2019; 6: e521\u2013e529.","DOI":"10.1016\/S2352-3026(19)30115-2"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja J, Oriol A, et al. Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM): Phase 1\/2 Results from MonumenTAL-1. Blood. 2022; 140: 384\u2013387.","DOI":"10.1182\/blood-2022-159707"},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"Lancman G, Lozada K, Athar N, Jacobs S, Doucette J, Cho HJ, et al. Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. Clinical Lymphoma, Myeloma & Leukemia. 2021; 21: e470\u2013e476.","DOI":"10.1016\/j.clml.2020.12.026"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"Hammons LR, Szabo A, Janardan A, Dhakal B, Chhabra S, D\u2019Souza A, et al. Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma. JAMA Network Open. 2022; 5: e2238961.","DOI":"10.1001\/jamanetworkopen.2022.38961"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P, et al. Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. Blood. 2022; 139: 1409\u20131412.","DOI":"10.1182\/blood.2021014989"},{"key":"ref118","doi-asserted-by":"crossref","unstructured":"D\u2019Souza A, Shah N, Rodriguez C, Voorhees PM, Weisel K, Bueno OF, et al. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen \u00d7 CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed\/Refractory Multiple Myeloma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2022; 40: 3576\u20133586.","DOI":"10.1200\/JCO.22.01504"},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer Journal. 2023; 13: 116.","DOI":"10.1038\/s41408-023-00879-7"},{"key":"ref120","doi-asserted-by":"crossref","unstructured":"Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, et al. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024; 109: 906\u2013914.","DOI":"10.3324\/haematol.2023.283590"},{"key":"ref121","doi-asserted-by":"crossref","unstructured":"Rodriguez-Otero P, D\u2019Souza A, Reece D, Van de Donk N, Chari A, Krishnan A, et al. Teclistamab in combination with daratumumab, a novel, immunotherapy based approach for the treatment of relapsed\/refractory multiple myeloma: updated phase 1b results. HemaSphere. 2022; 6: 89\u201390.","DOI":"10.1097\/01.HS9.0000843644.02496.66"},{"key":"ref122","doi-asserted-by":"crossref","unstructured":"van de Donk N, Bahlis N, Mateos M, Weisel K, Dholaria B, Garfall A, et al. Novel combination immunotherapy for the treatment of relapse\/refractory multiple myeloma: updated phase 1b results for talquetamab (A GPRC5D x CD3 bispecific antibody) in combination with daratumumab. HemaSphere. 2022; 6: 84\u201385.","DOI":"10.1097\/01.HS9.0000843624.82943.92"},{"key":"ref123","doi-asserted-by":"crossref","unstructured":"Searle E, Quach H, Wong SW, Costa LJ, Hulin C, Janowski W, et al. Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study. Blood. 2022; 140: 394\u2013396.","DOI":"10.1182\/blood-2022-159711"},{"key":"ref124","doi-asserted-by":"crossref","unstructured":"Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-Manrique L, D\u00edaz de Heredia C, Fortuny-Guasch C, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2021; 49: 215\u2013231.","DOI":"10.1007\/s15010-020-01521-5"},{"key":"ref125","doi-asserted-by":"crossref","unstructured":"Lancman G, Sastow DL, Cho HJ, Jagannath S, Madduri D, Parekh SS, et al. Bispecific Antibodies in Multiple Myeloma: Present and Future. Blood Cancer Discovery. 2021; 2: 423\u2013433.","DOI":"10.1158\/2643-3230.BCD-21-0028"},{"key":"ref126","doi-asserted-by":"crossref","unstructured":"Raje N, Bahlis NJ, Costello C, Dholaria B, Solh M, Levy MY, et al. Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma. Blood. 2022; 140: 388\u2013390.","DOI":"10.1182\/blood-2022-166494"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"Trudel S, Cohen AD, Krishnan AY, Fonseca R, Spencer A, Berdeja JG, et al. Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study. Blood. 2021; 138: 157.","DOI":"10.1182\/blood-2021-147983"},{"key":"ref128","doi-asserted-by":"crossref","unstructured":"Carlo-Stella C, Mazza R, Manier S, Facon T, Yoon SS, Koh Y, et al. RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study. Blood. 2022; 140: 397\u2013399.","DOI":"10.1182\/blood-2022-157988"},{"key":"ref129","doi-asserted-by":"crossref","unstructured":"Einsele H, Rasche L, Topp MS, Martin Kort\u00fcm K, Duell J. The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT. Bone Marrow Transplantation. 2019; 54: 721\u2013726.","DOI":"10.1038\/s41409-019-0596-z"},{"key":"ref130","doi-asserted-by":"crossref","unstructured":"Harrison SJ, Minnema MC, Lee HC, Spencer A, Kapoor P, Madduri D, et al. A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE\u00ae (bispecific T-cell engager) Molecule, in Relapsed\/Refractory (RR) Multiple Myeloma (MM). Blood. 2020; 136: 28\u201329.","DOI":"10.1182\/blood-2020-134063"},{"key":"ref131","doi-asserted-by":"crossref","unstructured":"Elmeliegy M, Viqueira A, Vandendries E, Hickman A, Hibma J, Lon HK, et al. Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma. Blood. 2022; 140: 7174\u20137175.","DOI":"10.1182\/blood-2022-169971"},{"key":"ref132","doi-asserted-by":"crossref","unstructured":"Hamadeh IS, Shekarkhand T, Rueda CJ, Firestone RS, Wang AX, Korde N, et al. Patterns of CRS with Teclistamab in Relapsed\/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy. Blood Advances. 2024. (online ahead of print)","DOI":"10.1182\/bloodadvances.2024012724"},{"key":"ref133","doi-asserted-by":"crossref","unstructured":"Niesvizky R, Arnulf B, Mohty M, Nooka AK, Manier S, Tomasson M, et al. Clinical Factors Associated with Cytokine Release Syndrome and Dosing Recommendations for Restarting Elranatamab Following an Interruption. Blood. 2023; 142: 3384.","DOI":"10.1182\/blood-2023-182166"},{"key":"ref134","doi-asserted-by":"crossref","unstructured":"Cohen YC, Morillo D, Gatt ME, Sebag M, Kim K, Min CK, et al. First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). Journal of Clinical Oncology. 2023; 41: 8002.","DOI":"10.1200\/JCO.2023.41.16_suppl.8002"},{"key":"ref135","doi-asserted-by":"crossref","unstructured":"Scott SA, Marin EM, Maples KT, Joseph NS, Hofmeister CC, Gupta VA, et al. Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood Cancer Journal. 2023; 13: 191.","DOI":"10.1038\/s41408-023-00963-y"},{"key":"ref136","doi-asserted-by":"crossref","unstructured":"Kowalski A, Lykon JL, Diamond B, Coffey D, Kaddoura M, Maura F, et al. Tocilizumab Prophylaxis for Patients Treated with Teclistamab: A Single-Center Experience. Blood. 2023; 142: 4709.","DOI":"10.1182\/blood-2023-187086"},{"key":"ref137","doi-asserted-by":"crossref","unstructured":"Laheij AMGA, van de Donk NWCJ. Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2023; 32: 20.","DOI":"10.1007\/s00520-023-08233-0"},{"key":"ref138","doi-asserted-by":"crossref","unstructured":"Fleischer A, Roll M, Panther F, Gelbrich G, Reinhardt F, Riedhammer C, et al. Taste Abnormalities Emerging during Anti-Myeloma Therapies Including GPRC5D x CD3 Bispecific Antibody Talquetamab. Blood. 2023; 142: 2403.","DOI":"10.1182\/blood-2023-186663"},{"key":"ref139","doi-asserted-by":"crossref","unstructured":"Touzeau C, Chari A, Schinke C, Minnema MC, Berdeja J, Oriol A, et al. Health-Related Quality of Life in Patients with Relapsed\/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1. Blood. 2022; 140: 4447\u20134449.","DOI":"10.1182\/blood-2022-162555"},{"key":"ref140","doi-asserted-by":"crossref","unstructured":"Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nature Reviews. Cancer. 2021; 21: 298\u2013312.","DOI":"10.1038\/s41568-021-00339-z"},{"key":"ref141","doi-asserted-by":"crossref","unstructured":"Truger MS, Duell J, Zhou X, Heimeshoff L, Ruckdeschel A, John M, et al. Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM. Blood Advances. 2021; 5: 3794\u20133798.","DOI":"10.1182\/bloodadvances.2021004418"},{"key":"ref142","doi-asserted-by":"crossref","unstructured":"Da Vi\u00e0 MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nature Medicine. 2021; 27: 616\u2013619.","DOI":"10.1038\/s41591-021-01245-5"},{"key":"ref143","doi-asserted-by":"crossref","unstructured":"Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nature Communications. 2021; 12: 868.","DOI":"10.1038\/s41467-021-21177-5"},{"key":"ref144","doi-asserted-by":"crossref","unstructured":"Han S, Munawar U, Haertle L, Vogt C, Nerreter S, Teufel E, et al. Functional Characterization of GPRC5D alteration and Its Impact on Talquetamab Resistance in Relapsed\/ Refractory Multiple Myeloma. Blood. 2023; 142: 3323.","DOI":"10.1182\/blood-2023-181607"},{"key":"ref145","doi-asserted-by":"crossref","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nature Medicine. 2023; 29: 2295\u20132306.","DOI":"10.1038\/s41591-023-02491-5"},{"key":"ref146","doi-asserted-by":"crossref","unstructured":"Chen H, Li M, Xu N, Ng N, Sanchez E, Soof CM, et al. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. Leukemia Research. 2019; 81: 62\u201366.","DOI":"10.1016\/j.leukres.2019.04.008"},{"key":"ref147","doi-asserted-by":"crossref","unstructured":"Pont MJ, Hill T, Cole GO, Abbott JJ, Kelliher J, Salter AI, et al. \u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019; 134: 1585\u20131597.","DOI":"10.1182\/blood.2019000050"},{"key":"ref148","doi-asserted-by":"crossref","unstructured":"Geis M, Nowotny B, Bohn MD, Kouhestani D, Einsele H, Bumm T, et al. Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments. Communications Biology. 2021; 4: 44.","DOI":"10.1038\/s42003-020-01558-0"},{"key":"ref149","doi-asserted-by":"crossref","unstructured":"Dekhtiarenko I, Lelios I, Jacob W, Schneider M, Weisser M, Carlo-Stella C, et al. Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed\/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody. Blood. 2023; 142: 1948.","DOI":"10.1182\/blood-2023-177669"},{"key":"ref150","doi-asserted-by":"crossref","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nature Reviews. Drug Discovery. 2017; 16: 315\u2013337.","DOI":"10.1038\/nrd.2016.268"},{"key":"ref151","doi-asserted-by":"crossref","unstructured":"Kawano Y, Moschetta M, Manier S, Glavey S, G\u00f6rg\u00fcn GT, Roccaro AM, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunological Reviews. 2015; 263: 160\u2013172.","DOI":"10.1111\/imr.12233"},{"key":"ref152","doi-asserted-by":"crossref","unstructured":"Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015; 125: 3049\u20133058.","DOI":"10.1182\/blood-2014-11-568881"},{"key":"ref153","doi-asserted-by":"crossref","unstructured":"Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023; 41: 711\u2013725.e6.","DOI":"10.1016\/j.ccell.2023.02.008"},{"key":"ref154","doi-asserted-by":"crossref","unstructured":"Mouhieddine TH, Van Oekelen O, Melnekoff DT, Li J, Ghodke-Puranik Y, Lancman G, et al. Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed\/refractory myeloma. Blood Advances. 2023; 7: 1056\u20131064.","DOI":"10.1182\/bloodadvances.2022007923"},{"key":"ref155","doi-asserted-by":"crossref","unstructured":"Keller AL, Parzych SE, Reiman LT, Walker ZJ, Forsberg PA, Sherbenou DW. BCMAxCD3 Bispecific Antibody Elranatamab Is Effective in Patient Myeloma Relapsed after BCMA CAR-T. Blood. 2023; 142: 4684.","DOI":"10.1182\/blood-2023-187385"},{"key":"ref156","doi-asserted-by":"crossref","unstructured":"Vishwamitra D, Skerget S, Cortes D, Perova T, Lau O, Davis C, et al. Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1\/2 MajesTEC-1 Study of Patients with Relapsed\/Refractory Multiple Myeloma. Blood. 2023; 142: 455.","DOI":"10.1182\/blood-2023-173550"},{"key":"ref157","doi-asserted-by":"crossref","unstructured":"Firestone R, McAvoy D, Shekarkhand T, Serrano E, Hamadeh IS, Wang A, et al. Evaluating Tumor-Intrinsic and Patient-Specific Mechanisms of Resistance to Teclistamab in Anti-BCMA Exposed and Na\u00efve Multiple Myeloma. Blood. 2023; 142: 333.","DOI":"10.1182\/blood-2023-187467"},{"key":"ref158","doi-asserted-by":"crossref","unstructured":"Vishwamitra D, Skerget S, Cortes D, Lau O, Davis C, Renaud T, et al. Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed\/Refractory Multiple Myeloma from the Phase 1\/2 MonumenTAL-1 Study. Blood. 2023; 142: 1933.","DOI":"10.1182\/blood-2023-187755"},{"key":"ref159","doi-asserted-by":"crossref","unstructured":"G\u00f6rg\u00fcn G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, et al. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2015; 21: 4607\u20134618.","DOI":"10.1158\/1078-0432.CCR-15-0200"},{"key":"ref160","doi-asserted-by":"crossref","unstructured":"Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-\u03b3 and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007; 110: 296\u2013304.","DOI":"10.1182\/blood-2006-10-051482"},{"key":"ref161","doi-asserted-by":"crossref","unstructured":"Atanackovic D, Luetkens T, Kr\u00f6ger N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia. 2014; 28: 993\u20131000.","DOI":"10.1038\/leu.2013.310"},{"key":"ref162","doi-asserted-by":"crossref","unstructured":"Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. 2013; 27: 464\u2013472.","DOI":"10.1038\/leu.2012.213"},{"key":"ref163","doi-asserted-by":"crossref","unstructured":"Ishibashi M, Tamura H, Sunakawa M, Kondo-Onodera A, Okuyama N, Hamada Y, et al. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1. Cancer Immunology Research. 2016; 4: 779\u2013788.","DOI":"10.1158\/2326-6066.CIR-15-0296"},{"key":"ref164","doi-asserted-by":"crossref","unstructured":"Cattaneo I, Choblet S, Valgardsdottir R, Roth M, Massafra A, Beeg M, et al. Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1. Antibodies (Basel, Switzerland). 2024; 13: 15.","DOI":"10.3390\/antib13010015"},{"key":"ref165","doi-asserted-by":"crossref","unstructured":"Nair-Gupta P, Rudnick SI, Luistro L, Smith M, McDaid R, Li Y, et al. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment. Blood Cancer Journal. 2020; 10: 65.","DOI":"10.1038\/s41408-020-0331-4"},{"key":"ref166","doi-asserted-by":"crossref","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I\/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2016; 34: 4381\u20134389.","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"ref167","doi-asserted-by":"crossref","unstructured":"Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A, et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 2017; 31: 2181\u20132190.","DOI":"10.1038\/leu.2017.41"},{"key":"ref168","doi-asserted-by":"crossref","unstructured":"Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, P\u00e9rez-Gracia JL, et al. Cytokines in clinical cancer immunotherapy. British Journal of Cancer. 2019; 120: 6\u201315.","DOI":"10.1038\/s41416-018-0328-y"},{"key":"ref169","doi-asserted-by":"crossref","unstructured":"Casey M, Lee C, Hoyte SM, Johnston RL, Kwok WY, Law SC, et al. Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy. Haematologica. 2024. (online ahead of print)","DOI":"10.3324\/haematol.2023.284435"},{"key":"ref170","doi-asserted-by":"crossref","unstructured":"Wu L, Seung E, Xu L, Rao E, Lord DM, Wei RR, et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nature Cancer. 2020; 1: 86\u201398.","DOI":"10.1038\/s43018-019-0004-z"},{"key":"ref171","doi-asserted-by":"crossref","unstructured":"Viardot A, Bargou R. Bispecific antibodies in haematological malignancies. Cancer Treatment Reviews. 2018; 65: 87\u201395.","DOI":"10.1016\/j.ctrv.2018.04.002"},{"key":"ref172","doi-asserted-by":"crossref","unstructured":"Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Molecular Therapy: the Journal of the American Society of Gene Therapy. 2014; 22: 102\u2013111.","DOI":"10.1038\/mt.2013.240"},{"key":"ref173","doi-asserted-by":"crossref","unstructured":"Liu X, Barrett DM, Jiang S, Fang C, Kalos M, Grupp SA, et al. Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer Journal. 2016; 6: e430.","DOI":"10.1038\/bcj.2016.38"},{"key":"ref174","doi-asserted-by":"crossref","unstructured":"Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. Journal of the National Cancer Institute. 2004; 96: 1593\u20131603.","DOI":"10.1093\/jnci\/djh299"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/29\/6\/10.31083\/j.fbl2906216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T09:17:36Z","timestamp":1732699056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/29\/6\/10.31083\/j.fbl2906216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":174,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"alternative-id":["S2768-6701(24)01316-9"],"URL":"https:\/\/doi.org\/10.31083\/j.fbl2906216","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"article-number":"216"}}